Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience

Borody, Thomas J.; Wettstein, Antony; Campbell, John; Leis, Sharyn; Torres, Margaux; Finlayson, Sarah; Nowak, Adriana

doi:10.14309/00000434-201210001-01644

Cited by 28 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition the follow up period was highly variable from about 1 week (100) to 15 years. (112) FMT has been applied beyond the treatment of CDI where its use is well established, to ulcerative colitis (10,83,84,(87)(88)(89)(90)(91)(92)(93)(94)(95)(96)(97)(98)(99) Crohn's disease (92,(100)(101)(102)(103)(104)(105)(106)(107) and mixed IBD. (109) Pioneering application in patients with constipation, (105,112) metabolic syndrome (9) and IBS (105,111) has been reported, raising questions as to the exact pathophysiology of these conditions.…”

Section: Discussionmentioning

confidence: 99%

“…Use in all forms IBD is the second most commonly reported indication for FMT, though the numbers of patients are small, 278 (17.8%). Some authors reporting successful outcomes (89,98,99,102,103,106,107,109,110) while others are more guarded, reporting more variable results or no discernible improvement. (10,91,93,101,104) In a relapsing and remitting condition the significance of adverse events such as flares and deteriorations are difficult to delineate the natural history of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Excluding the RCT for UC previously discussed, (9) 226 of the 1555 ascertained underwent FMT primarily for inflammatory bowel disease. Amongst these were 159 procedures for ulcerative colitis (83,(87)(88)(89)(90)(91)(92)(93)(94)(95)(96)(97)(98)(99)(100) and 67 for Crohn's. (92,(100)(101)(102)(103)(104)(105)(106)(107) In addition eight patients underwent FMT for pouchitis following restorative proctocolectomy for ulcerative colitis, (108) three for mixed UC/Crohns (109) or IBD unspecified.…”

Section: Fmt To Treat Inflammatory Bowel Diseasementioning

confidence: 99%

“…(90,93) Publications ranged from four single case reports (99,106,107,110) to series ranging from 3 (97,109) to 62 patients. (89)…”

Section: Fmt To Treat Inflammatory Bowel Diseasementioning

confidence: 99%

See 3 more Smart Citations

Adverse events in faecal microbiota transplant: a review of the literature

Baxter

Colville

2016

Journal of Hospital Infection

150

122

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Fmt To Treat Inflammatory Bowel Diseasementioning

confidence: 99%

“…(90,93) Publications ranged from four single case reports (99,106,107,110) to series ranging from 3 (97,109) to 62 patients. (89)…”

Section: Fmt To Treat Inflammatory Bowel Diseasementioning

confidence: 99%

See 2 more Smart Citations

Adverse events in faecal microbiota transplant: a review of the literature

Baxter

Colville

2016

Journal of Hospital Infection

150

122

View full text Add to dashboard Cite

show abstract

“…difficile infection has prompted a surge of interest in evaluating its efficacy as a treatment intervention in other diseases and disorders where perturbations to the microbiota are thought to play a role in pathogenesis and severity, including inflammatory bowel disease, where the first case report was published in 1989 . Since then, some authors have reported positive results, others have reported variable results or no observed clinical improvement . The strongest evidence for FMT in inflammatory bowel disease comes from 4 double‐blind randomised control trials, all of which were performed on patients with ulcerative colitis.…”

Section: Microbiota As a Therapeutic Target In Inflammatory Bowel Dismentioning

confidence: 99%

Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management

Mcilroy

Ianiro

Mukhopadhya

et al. 2017

Aliment Pharmacol Ther

154

120

View full text Add to dashboard Cite

show abstract

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

Costello

Hughes

Waters

et al. 2019

JAMA

596

612

View full text Add to dashboard Cite

IMPORTANCE High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity. OBJECTIVE To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool. DESIGN, SETTING, AND PARTICIPANTS A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017. INTERVENTIONS Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months. MAIN OUTCOMES AND MEASURES The primary outcome was steroid-free remission of UC, defined as a total Mayo score of Յ2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events. RESULTS Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group. CONCLUSIONS AND RELEVANCE In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety.

show abstract

Fecal Microbiota Transplantation in Ulcerative Colitis: Review of 24 Years Experience

Cited by 28 publications

References 0 publications

Adverse events in faecal microbiota transplant: a review of the literature

Adverse events in faecal microbiota transplant: a review of the literature

Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management

Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

Contact Info

Product

Resources

About